김명곤 연구실은 순환기내과를 중심으로 급성심근경색과 관상동맥질환의 진단·치료·예후 평가를 연구하며, 경피적 관상동맥중재술의 임상 성적, 심혈관 영상 기반 병변 분석, 항혈소판 치료 전략뿐 아니라 내피전구세포와 혈관재생 기전을 포함한 허혈성 심질환의 회복 메커니즘까지 아우르는 중개 및 임상 연구를 수행하고 있다.
RESULT OF A TRIAL FOR EVALUATING ADDITIONAL BENEFIT OF CILOSTAZOL TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH LONG OR MULTIVESSEL CORONARY ARTERY DISEASE UNDERWENT BIOLIMUS–ELUTING STENT IMPLANTATION (ABCD TRIAL)
Young Jin Youn, Jun‐Won Lee, Sung Gyun Ahn, Seung–Hwan Lee, Junghan Yoon, Bong‐Ki Lee, Byung Ok Kim, Cheol Woong Yu, Dong Woon Jeon, Hyuck Moon Kwon, Hyun Min Choe, Jang Hyun Cho, Keum Soo Park, Kook Jin Chun, Kyoo Rok Han, Kyung Soo Kim, Myeong Kon Kim, Myung Ki Hong, Sang Yong Yoo, Seung‐Woon Rha, Young Joon Hong, Yun Hyeong Cho
Combined Assessments of Biochemical Markers and ST-Segment Resolution Provide Additional Prognostic Information for Patients With ST-Segment Elevation Myocardial Infarction
Jong Shin Woo, Jin Man Cho, Soo–Joong Kim, Myeong Kon Kim, Chong Jin Kim
Korean Circulation Journal
Assessment of biomarkers upon admission and ST-segment resolution are strong predictors of clinical outcomes. The combination of these data provides additive information about prognosis at an early point in the disease progression and further improves risk stratification for STEMI.